-
Product Insights
NewPlasma Kallikrein – Drugs In Development, 2024
The Plasma Kallikrein pipeline drugs market research report outlays comprehensive information on the Plasma Kallikrein targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Immunology, Ophthalmology, Infectious Disease, and Respiratory which include indications of Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), Angioedema, Diabetic Macular Edema, Diabetic Retinopathy, Coronavirus Disease 2019 (COVID-19), and Acute Respiratory Distress Syndrome. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Recombinant Plasma Gelsolin Replacement For Infectious Disease in Acute Lung Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Recombinant Plasma Gelsolin Replacement For Infectious Disease in Acute Lung Injury report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Recombinant Plasma Gelsolin Replacement...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Carfilzomib in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Carfilzomib in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Carfilzomib in Plasma Cell Neoplasm Drug Details: Carfilzomib (Kyprolis) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Daratumumab in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Daratumumab in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Daratumumab in Plasma Cell Neoplasm Drug Details: Daratumumab ((HuMax-CD38, JNJ-54767414, Darzalex,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bortezomib in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bortezomib in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bortezomib in Plasma Cell Neoplasm Drug Details: Bortezomib (Velcade) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RD-138 in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RD-138 in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RD-138 in Plasma Cell Neoplasm Drug Details: RD-138 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CT-0594CP CAR-T Cells in Plasma Cell Neoplasm
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CT-0594CP CAR-T Cells in Plasma Cell Neoplasm report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CT-0594CP CAR-T Cells in Plasma Cell Neoplasm Drug Details:...
-
Product Insights
NewPlasma Cell Neoplasm – Drugs In Development, 2024
Empower your strategies with our Plasma Cell Neoplasm – Drugs In Development, 2024 report and make more profitable business decisions. Plasma Cell Neoplasm or plasma cell cancer is a group of diseases involving B-cells. These tumors are found in soft tissues that can be malignant or benign. Multiple Myeloma, lymphoplasmacytic lymphoma, plasmacytoma are the types of plasma cell cancers. Of all three multiple Myeloma is the most common and aggressive form. Age, chronic infection, exposure to radiation, hereditary factors, are some...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lanadelumab in Angioedema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lanadelumab in Angioedema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lanadelumab in Angioedema Drug Details: Lanadelumab (Takhzyro) recombinant, fully human, monoclonal antibody...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sebetralstat in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sebetralstat in Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sebetralstat in Hereditary Angioedema (HAE)...